glp-1 nad Cardiovascular Protection with a Long-Acting Receptor Agonist Liraglutide: An Experimental Update Compounded GLP-1 - Semaglutide &

Supreme Court's June 25, 2026 decision in Mullin v

Distributions for qualified medical expenses

A 2023 systematic review evaluated 17 studies on transdermal weight-loss patches broadly and concluded that no high-quality evidence supports the efficacy of any non-prescription transdermal patch for weight reduction

Approval of tirzepatide (brand name Mounjaro/Zepbound), an even more efficacious medication, soon followed in 2023

A recent case report of a woman who was diagnosed with MTC while on a GLP-1 agonist showed no change in her calcitonin levels ( Gastroenterology

As GLP-1 therapy leads to weight loss, improved glycemic control, and potentially reduced inflammation, visceral fat deposits may decrease along with fat in other areas